Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV:KHRN), (OTCQX:KHRNF), (Frankfurt:A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announced today that Alvaro Torres, Khiron CEO and Chris Naprawa, Khiron Chairman, will present live at VirtualInvestorConferences.com on September 10, 2020.
Date: Thursday, September 10, 2020
Time: 4:30 p.m. ET
Registration link: https://www.virtualinvestorconferences.com/events/event-details/kcsa-cannabis-investor-conference
VirtualInvestorConferences.com is an investor-focused online conference series that provides an interactive forum for publicly-traded companies to meet and present directly with investors.
Attendees of the event will have an opportunity to ask questions in real time, and an archived webcast will be available after the event for those who are not able to join the event live on the day of the conference. Pre-registration is recommended for attendees who wish to receive updates prior to the event.
Learn more about the event at www.virtualinvestorconferences.com.
Recent Company Highlights:
- Issued more than 1,500 medical cannabis prescriptions since the receipt of the authorization to manufacture and commercialize high-THC medical cannabis in Colombia
- Expanded reach of Khiron’s medical cannabis e-learning platform to UK market through partnership with a clinician-led organization Medical Cannabis Clinicians Society
- Launched teleconsultation platform to meet essential needs of its patient network in Colombia
- Delivered first medical cannabis prescriptions for patients participating in Project Twenty21 in the UK
- Entered the German medical cannabis market signing an agreement with Nimbus Health for Khiron branded medical cannabis product import and sales
- Signed a distribution deal for the Kuida CBD cosmeceutical brand with DNO Group serving the Hong Kong market
About Khiron Life Sciences Corp.
Khiron is a vertically integrated medical and CPG cannabis company with core operations in Latin America, and operational activity in Europe and North America. Khiron is the leading cannabis company in Colombia and the first company licensed in Colombia for the cultivation, production, domestic distribution, and international export of both low and high THC medical cannabis products. The Company has presence in Mexico, Peru, Uruguay, Brazil, UK, Spain and Germany, where it is positioned to begin sales of medical cannabis.
Leveraging its first-mover advantage, and patient oriented approach, Khiron combines global scientific expertise, product innovation, agricultural infrastructure, wholly-owned medical clinics, and online doctor education programs to drive prescription and brand loyalty to address priority medical conditions. Its Wellbeing unit launched the first branded CBD skincare brand in Colombia, with KuidaTM now marketed in multiple jurisdictions in Latin America, the US and UK. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram @khironlife.
This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
View original content to download multimedia:http://www.prnewswire.com/news-releases/khiron-to-present-at-live-investor-conference-on-september-10th-301123478.html
SOURCE Khiron Life Sciences Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2020/03/c0607.html
Investor Contact: Paola Ricardo, E: email@example.com, T: +1 (786) 233-7411; Media Contact: Jon Packer, Vice President, Communications, T: +1 (416) 543-9179, E: firstname.lastname@example.org; Khiron Europe: Tejinder Virk, Europe President, T: +44 (0) 7912 741 995, E: email@example.comCopyright CNW Group 2020
News Provided by Canada Newswire via QuoteMedia